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Methods. Since 5-2012 ﬁfteenNCCN PCa patientswere treatedwith helical tomotherapy. Approved by clinical research ethics com-
mittee. Exclusion criteria: Gleason score≥8, PSA>20, cT3b-4, cN1, cM1, IPSS≥20, history of acuteurinary retention. CT-simulation
using CombiﬁxTM with empty rectum and 200ml bladder ﬁlled through urine catheter. CTV included prostate± seminal vesicles.
PTV margins were 3–10mm. Total dose to 95% PTV was 43.84–45.20Gy in 8 fx of 5.48–5.65Gy on alternate days, according to the
risk group (low vs. intermediate-high). EQD2=74.4–78.2Gy (a/b3) or 87.4–92.3Gy (a/b1.5). Rectal constraints: V43<10%, V40<15%,
V37<20%, V34<30%, V28<40%. MVCT for on-line correction in every fraction. Cleansing enema prior each fraction. Bladder
volume during irradiation was controlled through: (1) bladder ﬁlling using urine catheter (1st patient), or (2) measuring urine
volume right after every fraction to provide feedback about the delay between water intake and treatment. All men received
neoadjuvant-concomitant ADT.
Results. Patient characteristics: cT1 (53%), T2b (30%), T3a (17%), GS6 (46%), GS7 (54%), median PSA=8.2ng, median IPSS=5. CTCAE
acute GI toxicity: 0% grade 2, 54% grade 1 (abdominal pain, frequency, diarrhoea), 46% grade 0. GU ﬁgures: 7% grade 2 (dysuria),
66% grade 1 (dysuria, frequency, urgency, nocturia), 27% grade 0. In total, after 120 MVCT, the standard deviation of the mean
individual patient corrections in anterior–posterior direction was 1.5mm. Irradiation time was 520±30 s. A 25min time slot is
dedicated to every fraction.
Conclusion. To our knowledge, this is the ﬁrst clinical report about extreme hypofractionation in PCa using helical tomotherapy.
In this series high-dose radiotherapy delivered in eight fractions had an acceptable acute toxicity proﬁle.
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Introduction. Intermittent androgen deprivation for prostate-speciﬁc antigen (PSA) elevation after radiotherapy (RT) may improve
quality of life and delay hormone resistance.
Purpose. We compared biochemical control and quality of life with intermittent (6 months) versus continuous (36 months) andro-
gen deprivation in a noninferiority randomized trial in patients with biochemical progression (BR) after RT following Phoenix
PSA criteria.
Materials and methods. Seventy-seven patients were included in this multicentre phase III trial between 2005 and 2009. Median
follow-up was 2 years. Patients were stratiﬁed according Gleason score (GS), which was classiﬁed as low risk if GS<6 and 7 (3 + 4)
and high risk with GS of 7 (4 + 3) and >7. Patients were followed with PSA determinations and quality of life assessments (QLQ
C-30 and QLQ PR-25) every 6 months for a period of 3 years. BR was deﬁned as a PSA determination of 4 or >4ng/ml.
Results. Thirty-eight and 39 patients were included in intermittent and continuous group respectively. Mean age was 74.3 (±6.5).
Previous moderate comorbidity was present in 51 patients. TNM stage at the diagnostic was T1c (20.5%), T2a (20.5%), T2b-c
(24.7%) and T3a-b (33%). GS was low risk (as previously deﬁned) in 43 patients (58.1%) and high risk in 31 patients (41.9). GS was
well balanced between groups. BR was seen in 8 patients (distant metastases in one patient) in the intermittent group vs. 2 in
the continuous group. QLQ-C30 score did not show any statically difference between groups of hormonal treatment. QLQ PR-25
assessment showed statistically signiﬁcant changes in urinary symptoms between baseline and visit 9 between intermittent and
continuous deprivation (p-value=0.036) and the absolute value of the symptoms associated with hormone therapy at baseline
(p-value=0.037). Conclusions. In this preliminary analysis no statistical differences in BR were seen between intermittent (6
months) and continuous (36 months) hormonal deprivation.
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